Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

CV; the remaining eight patients tested positive for HCV, at an average of two years following the completion of treatment. The study found that these eight patients exhibited no consistency in age, gender or HCV genotype, and it has not been determined if these patients experienced a relapse or if they were re-infected with HCV.

"We at Roche are proud to be able to offer some hepatitis C patients the prospect of such a positive outcome with our currently-available therapies, but we also recognize the urgent need to further improve response rates," said Tom Klein, Vice President, Hepatology, Roche. "In addition to ongoing research with PEGASYS, Roche has the most comprehensive pipeline in the area, with four compounds currently in human development that target the virus in a number of different ways. The development of R1626 and partnerships with InterMune, Maxygen and Pharmasset, all underscore our long-term commitment to finding effective new therapies with the goal of successfully treating more patients with chronic hepatitis C."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS, are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... in Mice Transgenic for Human TNFa, LAUSANNE, ... (Debiopharm), a global independent biopharmaceutical,development company specialising ... presentation of preclinical results that,validate the mechanism ... vaccine, that inhibits inflammatory processes in animal,models ...
... 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned ... strong positive,results in studies of vaccines against ... proprietary AIPwLV(TM) vaccine technology. The,studies were conducted ... (CMB), the Contract Research Organization led by ...
Cached Medicine Technology:Preclinical Update - Debio-0512 Therapeutic Vaccine for the,Treatment of Chronic and Acute Inflammatory Conditions 2Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased ... Clinical Pharmacy Services at North Carolina State’s College of ... 2015 Beal Award for Distinguished Volunteer Service—the organization’s highest ... the contributions of volunteer experts to direct its work ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... ... virus. The latest developments on the flu virus can be accessed at PediatricSuperSite.com ... ... News and Infectious Diseases in Children offer a dedicated link to breaking news surrounding ...
... WASHINGTON, Sept. 16 Reform opponents continue to spread myths about ... the nonsensical claim that the federal government has no constitutionally valid role ... Medicare and other popular federal health reforms. , , ... violate the 10th amendment." , , ...
... WASHINGTON, Sept. 16 Today U.S. Sen. Max Baucus ... Act of 2009" that will be marked-up in the Senate ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , ... plans that cover all elective abortions and moves well beyond ...
... health care and obesity, but beverage industry balks at proposal ... of 1 cent per ounce of soda and other sugary ... $14.9 billion the first year alone, health experts say. , ... also funding programs to prevent obesity, say a group of ...
... , WASHINGTON, Sept. 16 /PRNewswire-USNewswire/ ... from President and CEO Karen Ignagni: , , "Senator ... health care reform this year and challenged all stakeholders to contribute to ... a very important step in the health care reform process. ...
... DIEGO, Sept. 16 SpectraScience, Inc. (OTC Bulletin Board: SCIE), a ... for premarket approval (PMA) relating to key enhancements of its WavSTAT ... The Company can now begin commercial distribution of the enhanced WavSTAT ... said, "We are pleased to now be able to bring to ...
Cached Medicine News:Health News:Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus: 2Health News:Infectious Disease News and Infectious Diseases in Children Provide Online Reports Dedicated to Influenza A (H1N1) virus: 3Health News:Health Insurance Reform DAILY MYTHBUSTER: 'Constitutionality of Health Insurance Reform' 2Health News:Health Insurance Reform DAILY MYTHBUSTER: 'Constitutionality of Health Insurance Reform' 3Health News:Family Research Council: Senator Baucus Undermines President Obama's Abortion Funding Claim 2Health News:'Soda Tax' Wins Health Experts' Support 2Health News:'Soda Tax' Wins Health Experts' Support 3Health News:'Soda Tax' Wins Health Experts' Support 4Health News:AHIP Statement on Release of Finance Committee Chairman's Mark 2Health News:SpectraScience Receives FDA Approval for Enhancements to WavSTAT(R) Optical Biopsy System 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: